Protagonist Therapeutics, Inc Earnings Per Share (Diluted)
Protagonist Therapeutics, Inc (PTGX) reported Earnings Per Share (Diluted) of $2.29 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-05
- Protagonist Therapeutics, Inc earnings per share, diluted for the quarter ending 2026-06-30 was $2.29.
- Protagonist Therapeutics, Inc earnings per share, diluted for the quarter ending 2026-03-31 was $0.05.
- Protagonist Therapeutics, Inc earnings per share, diluted for the quarter ending 2025-12-31 was -$0.69, a 134.99% decline year-over-year.
- Protagonist Therapeutics, Inc earnings per share, diluted for the quarter ending 2025-09-30 was -$0.62.
- Protagonist Therapeutics, Inc earnings per share, diluted for fiscal 2025 was -$2.05, a 148.46% decline from fiscal 2024.
- Protagonist Therapeutics, Inc earnings per share, diluted for fiscal 2024 was $4.23.
- Protagonist Therapeutics, Inc earnings per share, diluted for fiscal 2023 was -$1.39.
- Protagonist Therapeutics, Inc earnings per share, diluted for fiscal 2022 was -$2.60.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.29 10-Q · filed 2026-08-05 | $2.35 10-Q · filed 2026-08-05 | $1.78 derived: net income ÷ weighted average shares · filed 2026-08-05 | $1.23 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | $0.05 10-Q · filed 2026-05-05 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$1.75 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.69 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.86 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.05 10-K · filed 2026-02-25 |
| 2025-09-30 | -$0.62 10-Q · filed 2025-11-06 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.35 10-Q · filed 2025-11-06 | $0.72 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.55 10-Q · filed 2026-08-05 | -$0.73 10-Q · filed 2026-08-05 | $1.33 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.82 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.19 10-Q · filed 2026-05-05 | $1.85 derived: net income ÷ weighted average shares · filed 2026-05-05 | $1.36 derived: net income ÷ weighted average shares · filed 2026-05-05 | $0.89 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2024-12-31 | $1.98 derived: net income ÷ weighted average shares · filed 2026-04-28 | $1.54 derived: net income ÷ weighted average shares · filed 2026-04-28 | $1.07 derived: net income ÷ weighted average shares · filed 2026-04-28 | $4.23 10-K · filed 2026-02-25 |
| 2024-09-30 | -$0.54 10-Q · filed 2025-11-06 | -$1.04 derived: net income ÷ weighted average shares · filed 2025-11-06 | $2.22 10-Q · filed 2025-11-06 | $2.77 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-06-30 | -$0.50 10-Q · filed 2025-08-06 | $2.77 10-Q · filed 2025-08-06 | $3.30 derived: net income ÷ weighted average shares · filed 2026-04-28 | $2.78 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-03-31 | $3.26 10-Q · filed 2025-05-06 | $3.78 derived: net income ÷ weighted average shares · filed 2026-04-28 | $3.28 derived: net income ÷ weighted average shares · filed 2026-04-28 | $2.70 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-12-31 | $0.45 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.39 10-K · filed 2026-02-25 |
| 2023-09-30 | -$0.58 10-Q · filed 2024-11-07 | -$1.25 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.91 10-Q · filed 2024-11-07 | -$2.60 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-06-30 | -$0.68 10-Q · filed 2024-08-06 | -$1.34 10-Q · filed 2024-08-06 | -$2.04 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.68 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-03-31 | -$0.67 10-Q · filed 2024-05-07 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.00 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.83 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2022-12-31 | -$0.69 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.33 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.60 10-K · filed 2025-02-21 |
| 2022-09-30 | -$0.64 10-Q · filed 2023-11-02 | -$1.47 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.90 10-Q · filed 2023-11-02 | -$2.67 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2022-06-30 | -$0.84 10-Q · filed 2023-08-03 | -$1.27 10-Q · filed 2023-08-03 | -$2.03 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.74 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2022-03-31 | -$0.43 10-Q · filed 2023-05-04 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.90 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.58 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2021-12-31 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.47 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.16 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.71 10-K · filed 2024-02-27 |
| 2021-09-30 | -$0.70 10-Q · filed 2022-11-08 | -$1.39 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.94 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$0.69 10-Q · filed 2022-08-04 | -$1.23 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$0.54 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$1.92 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |